Genitourinary Cancers | Specialty

New Strategies Enhance Care in mUC

November 25th 2020

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

FDA Approves Durvalumab for Fixed-Dose Use in NSCLC, Bladder Cancer Indications

November 20th 2020

November 20, 2020 - The FDA has approved durvalumab for an additional dosing option, a fixed dose of 1500 mg every 4 weeks, in the approved indications of unresectable stage III non-small cell lung cancer after chemoradiation and previously treated advanced bladder cancer.

Frontline Therapeutic Planning for Metastatic Renal Cell Carcinoma

November 18th 2020

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.

UGN-102 Elicits Durable Responses in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

November 17th 2020

November 17, 2020 - Primary chemoablation with UGN-102 was found to induce durable responses in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

Novel Mechanism of Action and Tolerability Makes Telaglenastat a Promising Player in RCC

November 17th 2020

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

November 14th 2020

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

Dr. George on the Specificity of Cabozantinib in RCC

November 13th 2020

Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.

Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

November 13th 2020

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Dr. Campbell on the Expanding Role of Cabozantinib in RCC

November 12th 2020

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

Dr. Hutson on Remaining Questions With the Durability of Immune Responses in RCC

November 12th 2020

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.